Shabihkhani Maryam, Telesca Donatello, Movassaghi Masoud, Naeini Yalda B, Naeini Kourosh M, Hojat Seyed Amin, Gupta Diviya, Lucey Gregory M, Ontiveros Michael, Wang Michael W, Hanna Lauren S, Sanchez Desiree E, Mareninov Sergey, Khanlou Negar, Vinters Harry V, Bergsneider Marvin, Nghiemphu Phioanh Leia, Lai Albert, Liau Linda M, Cloughesy Timothy F, Yong William H
Divison of Neuropathology, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, University of California-Los Angeles, 10833 LeConte Avenue, CHS13-145B, 90095, Los Angeles, CA, USA.
Department of Biostatistics, UCLA School of Public Health, Los Angeles, CA, USA.
J Neurooncol. 2017 Apr;132(2):351-358. doi: 10.1007/s11060-017-2377-0. Epub 2017 Feb 4.
Latino Americans are a rapidly growing ethnic group in the United States but studies of glioblastoma in this population are limited. We have evaluated characteristics of 21,184 glioblastoma patients from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute. This SEER data from 2001 to 2011 draws from 28% of the U.S.
Latinos have a lower incidence of GBM and present slightly younger than non-Latino Whites. Cubans present at an older age than other Latino sub-populations. Latinos have a higher incidence of giant cell glioblastoma than non-Latino Whites while the incidence of gliosarcoma is similar. Despite lower rates of radiation therapy and greater rates of sub-total resection than non-Latino Whites, Latinos have better 1 and 5 year survival rates. SEER does not record chemotherapy data. Survivals of Latino sub-populations are similar with each other. Age, extent of resection, and the use of radiation therapy are associated with improved survival but none of these variables are sufficient in a multivariate analysis to explain the improved survival of Latinos relative to non-Latino Whites. As molecular data is not available in SEER records, we studied the MGMT and IDH status of 571 patients from a UCLA database. MGMT methylation and IDH1 mutation rates are not statistically significantly different between non-Latino Whites and Latinos. For UCLA patients with available information, chemotherapy and radiation rates are similar for non-Latino White and Latino patients, but the latter have lower rates of gross total resection and present at a younger age.
拉丁裔美国人是美国一个快速增长的族裔群体,但针对该人群的胶质母细胞瘤研究有限。我们评估了来自美国国立癌症研究所监测、流行病学和最终结果(SEER)项目的21184例胶质母细胞瘤患者的特征。该SEER数据来自2001年至2011年,涵盖美国28%的人口。
拉丁裔胶质母细胞瘤发病率较低,发病年龄比非拉丁裔白人略小。古巴人的发病年龄比其他拉丁裔亚人群体大。拉丁裔巨细胞胶质母细胞瘤的发病率高于非拉丁裔白人,而胶质肉瘤的发病率相似。尽管与非拉丁裔白人相比,拉丁裔接受放疗的比例较低,次全切除的比例较高,但他们的1年和5年生存率更高。SEER未记录化疗数据。拉丁裔亚人群体的生存率彼此相似。年龄、切除范围和放疗的使用与生存率提高相关,但在多变量分析中,这些变量均不足以解释拉丁裔相对于非拉丁裔白人生存率提高的原因。由于SEER记录中没有分子数据,我们研究了来自加州大学洛杉矶分校数据库的571例患者的MGMT和IDH状态。非拉丁裔白人和拉丁裔之间的MGMT甲基化和IDH1突变率在统计学上无显著差异。对于有可用信息的加州大学洛杉矶分校患者,非拉丁裔白人和拉丁裔患者的化疗和放疗率相似,但后者的全切率较低,发病年龄较小。